Skymark Research Initiates Independent Research Coverage On PolyMedix, Inc.
Do you know when to trade PYMX ?
PYMX | Quote | Chart | News | PowerRating -- Skymark Research, a leading provider of small- and micro-cap independent investment research, today initiated coverage on PolyMedix, Inc. (OTCBB:PYMX). Skymark Research is currently offering a complimentary trial subscription. To view our research go to: www.skymarkresearch.com
About SMR:
Skymark Research is a leading provider of independent investment research in North America. Our services include research analysis on the small- and micro-cap markets, real-time news and financial data, market commentary and the SMR newsletter. Skymark Research's staff of small-cap investment professionals is dedicated to providing the small market's investment community with the tools and avenues necessary to make the important investment decisions. To view our research reports on a complimentary trial basis and take advantage of our other services, go to www.skymarkresearch.com and click on the complimentary trial subscription button on our home page, or go directly to our registration page at www.skymarkresearch.com/signup.php
The Skymark Research logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=6683
About PolyMedix, Inc. (OTCBB:PYMX)
PolyMedix is a publicly traded emerging biotechnology company focused on the development of novel drugs and biomaterials for the treatment of infectious diseases and acute cardiovascular disorders.
SMR Disclosure:
Skymarkresearch.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. Skymark Research has not been compensated by any of the above mentioned companies. Please read our report and visit our Web site, www.skymarkresearch.com, for complete risks and disclosures.
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: Skymark Research
CONTACT: Skymark Research
Dylan Boyle
202-657-6249
info@skymarkresearch.com
For full details on (PYMX) PYMX. (PYMX) has Short Term PowerRatings at TradingMarkets. Details on (PYMX) Short Term PowerRatings is available at This Link.
- PolyMedix Initiates Phase 1B Clinical Study With PMX-60056 To Reverse Low Molecular Weight Heparin - 03/18/10
- PolyMedix Presents PMX-30063 Antibiotic Data at TSIS 2010 - 03/16/10
- PolyMedix Presents PMX-30063 Antibiotic Data at 8th World Congress on Trauma, Shock, Inflammation and Sepsis -- TSIS 2010 - 03/11/10
- www.StockMarketingInc.com: Have You Heard Of Us!! Sign Up And Learn About Us!! MSOA,PYMX,ENTB,EVSO,PVCT,XCHO - 03/10/10
- StockProfiler.US: Penny Stock News for Tuesday: PolyMedix, Inc. & Emerging World Pharma Inc. - 03/10/10
- More News >>


